Characteristics of hematopoietic stem-cell transplant recipients
Case no. . | Diagnosis . | Age at HSCT, y . | Type of donor . | HLA allele compatibility . | Conditioning regimen for HSCT . | Source of HSCs . | aGVHD . | cGVHD . | Time from HSCT to sampling, d . | cGVHD at sampling . | Immunosuppressive therapy at sampling . | Percentage of donor area . |
---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | ALL | 26 | Unrelated | Match | CSI+CY+TBI | BM | II | Limited | 521 | Negative | None | 17.2 |
2 | AML | 53 | Related | Match | BU+CY | BM | None | Limited | 2529 | Positive | None | 0 |
3 | AML | 42 | Related | Match | BU+CY | BM | II | Limited | 569 | Negative | None | 0 |
4 | AML | 23 | Unrelated | Match | TBI+CY | BM | None | Limited | 1259 | Negative | None | 39.2 |
5 | AML | 45 | Related | Match | BU+CY | BM | I | Limited | 1657 | Negative | None | 23.8 |
6 | MDS | 18 | Related | Match | BU+CY | PB+BM | None | Extensive | 1811 | Positive | CsA | 0 |
7 | SAA | 23 | Related | Match | BU+CY | BM | I | Extensive | 2287 | Positive | FK | 15.1 |
8 | CML | 25 | Related | Match | BU+CY | PB | I | Extensive | 2252 | Positive | PSL | 0 |
9 | ALL | 55 | Unrelated | 2 locus mismatch | TBI+Flu+L-PAM | CB | I | Limited | 467 | Negative | None | 0 |
10 | ALL | 17 | Related | Match | TBI+CY | BM | I | Extensive | 999 | Positive | CsA+PSL | 72.9 |
11 | AML | 45 | Unrelated | 1 locus mismatch | TBI+CY | BM | None | Limited | 550 | Positive | None | 0 |
12 | AML | 33 | Unrelated | Match | CSI+CY+TBI | BM | II | Extensive | 1711 | Negative | None | 0 |
13 | AML | 26 | Related | Match | BU+CY | BM | None | Extensive | 305 | Positive | CsA+PSL+MMF | 8.9 |
14 | AML | 30 | Related | Match | BU+CY | BM | II | Extensive | 1580 | Positive | FK+PSL+MMF | 0 |
15 | ALL | 20 | Related | Match | BU+CY | BM | I | Limited | 1111 | Negative | None | 69.1 |
16 | ATL | 40 | Related | Match | TBI+CY | PB | None | Extensive | 1518 | Positive | CsA | 31.2 |
17 | AML | 49 | Unrelated | Match | TBI+CY | BM | None | Extensive | 426 | Positive | FK+PSL | 0 |
18 | ALL | 28 | Unrelated | 4 locus mismatch | CY+Flu+BU | CB | II | Extensive | 851 | Positive | None | 0 |
19 | AML | 17 | Related | Match | TBI+CY | PB | II | Extensive | 2107 | Positive | FK | 0 |
20 | AML | 42 | Related | Match | BU+CY | PB | I | Extensive | 1209 | Positive | FK+PSL | 0 |
21 | CML | 46 | Related | Match | BU+CY | BM | None | Limited | 2399 | Negative | None | 56.5 |
Case no. . | Diagnosis . | Age at HSCT, y . | Type of donor . | HLA allele compatibility . | Conditioning regimen for HSCT . | Source of HSCs . | aGVHD . | cGVHD . | Time from HSCT to sampling, d . | cGVHD at sampling . | Immunosuppressive therapy at sampling . | Percentage of donor area . |
---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | ALL | 26 | Unrelated | Match | CSI+CY+TBI | BM | II | Limited | 521 | Negative | None | 17.2 |
2 | AML | 53 | Related | Match | BU+CY | BM | None | Limited | 2529 | Positive | None | 0 |
3 | AML | 42 | Related | Match | BU+CY | BM | II | Limited | 569 | Negative | None | 0 |
4 | AML | 23 | Unrelated | Match | TBI+CY | BM | None | Limited | 1259 | Negative | None | 39.2 |
5 | AML | 45 | Related | Match | BU+CY | BM | I | Limited | 1657 | Negative | None | 23.8 |
6 | MDS | 18 | Related | Match | BU+CY | PB+BM | None | Extensive | 1811 | Positive | CsA | 0 |
7 | SAA | 23 | Related | Match | BU+CY | BM | I | Extensive | 2287 | Positive | FK | 15.1 |
8 | CML | 25 | Related | Match | BU+CY | PB | I | Extensive | 2252 | Positive | PSL | 0 |
9 | ALL | 55 | Unrelated | 2 locus mismatch | TBI+Flu+L-PAM | CB | I | Limited | 467 | Negative | None | 0 |
10 | ALL | 17 | Related | Match | TBI+CY | BM | I | Extensive | 999 | Positive | CsA+PSL | 72.9 |
11 | AML | 45 | Unrelated | 1 locus mismatch | TBI+CY | BM | None | Limited | 550 | Positive | None | 0 |
12 | AML | 33 | Unrelated | Match | CSI+CY+TBI | BM | II | Extensive | 1711 | Negative | None | 0 |
13 | AML | 26 | Related | Match | BU+CY | BM | None | Extensive | 305 | Positive | CsA+PSL+MMF | 8.9 |
14 | AML | 30 | Related | Match | BU+CY | BM | II | Extensive | 1580 | Positive | FK+PSL+MMF | 0 |
15 | ALL | 20 | Related | Match | BU+CY | BM | I | Limited | 1111 | Negative | None | 69.1 |
16 | ATL | 40 | Related | Match | TBI+CY | PB | None | Extensive | 1518 | Positive | CsA | 31.2 |
17 | AML | 49 | Unrelated | Match | TBI+CY | BM | None | Extensive | 426 | Positive | FK+PSL | 0 |
18 | ALL | 28 | Unrelated | 4 locus mismatch | CY+Flu+BU | CB | II | Extensive | 851 | Positive | None | 0 |
19 | AML | 17 | Related | Match | TBI+CY | PB | II | Extensive | 2107 | Positive | FK | 0 |
20 | AML | 42 | Related | Match | BU+CY | PB | I | Extensive | 1209 | Positive | FK+PSL | 0 |
21 | CML | 46 | Related | Match | BU+CY | BM | None | Limited | 2399 | Negative | None | 56.5 |
ALL indicates acute lymphoblastic leukemia; CSI, craniospinal irradiation; CY, cyclophosphamide; TBI, total body irradiation; BM, bone marrow; AML, acute myelogenous leukemia; BU, busulfan; MDS, myelodysplastic syndrome; PB, peripheral blood; CsA, cyclosporine A; SAA, severe aplastic anemia; FK, tacrolimus; CML, chronic myelogenous leukemia; PSL, prednisolone; Flu, fludarabine; L-PAM, melphalan; CB, cord blood; MMF, mycophenolate mofetil; and ATL, adult T-cell leukemia.